13 November 2024 - NICE has published final evidence-based recommendations on the use of teclistamab (Tecvayli) for the treatment of adults with relapsed and refractory multiple myeloma after three or more treatments.

Teclistamab is recommended as an option for the treatment of adults with relapsed and refractory multiple myeloma after 3 or more lines of treatment (including an immunomodulatory drug, a proteasome inhibitor and an anti-CD38 antibody) when the myeloma has progressed on the last treatment. 

It is only recommended if Janssen provides teclistamab according to the commercial arrangement.

Read NICE technology appraisal guidance